Esther M. van Wezel

Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel

Esther M. van Wezel, Lieke M. J. van Zogchel, Jalenka van Wijk et al. · JCO Precision Oncology · 2019 · 36 citations · Full text

Medicine, Cancer Biology, Oncology +15

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma

Esther M. van Wezel, Janine Stutterheim, Florentien M. Vree et al. · Pediatric Blood & Cancer · 2015 · 27 citations · Full text

Medicine, Hematology, Oncology +16

Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response

Esther M. van Wezel, Joep de Bruijne, Kevin Damman et al. · Open Forum Infectious Diseases · 2019 · 27 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Hypermethylated <i>RASSF1A</i> as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma

Lieke M. J. van Zogchel, Esther M. van Wezel, Jalenka van Wijk et al. · JCO Precision Oncology · 2020 · 23 citations · Full text

Medicine, Molecular Biology, Oncology +17

Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma

Esther M. van Wezel, Danny A. Zwijnenburg, Lily Zappeij‐Kannegieter et al. · Journal of Molecular Diagnostics · 2014 · 22 citations

Life Sciences, Genetics, Oncology +10